154 related articles for article (PubMed ID: 23597200)
21. The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.
Tong X; Zhang X; Fan J; Tong Y; Li S; Jin J; Yao H
Cancer Biol Ther; 2013 Apr; 14(4):370-7. PubMed ID: 23360784
[TBL] [Abstract][Full Text] [Related]
22. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
23. Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.
Jiang J; Gui F; He Z; Li L; Li Y; Li S; Wu X; Deng Z; Sun X; Huang X; Huang W; Han S; Zhang T; Wang Z; Jiao B; Song S; Wang H; Chen L; Zhou D; Liu Q; Ren R; Zhang J; Deng X
Cancer Res; 2017 Jan; 77(1):175-186. PubMed ID: 27758886
[TBL] [Abstract][Full Text] [Related]
24. Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.
Zhu X; Wang K; Zhang K; Zhu L; Zhou F
Toxicol Lett; 2014 May; 227(1):65-73. PubMed ID: 24680927
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
26. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
27. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
[TBL] [Abstract][Full Text] [Related]
28. Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.
Seidel J; Kunc K; Possinger K; Jehn C; Lüftner D
Biochem Biophys Res Commun; 2011 Oct; 414(1):226-32. PubMed ID: 21945930
[TBL] [Abstract][Full Text] [Related]
29. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.
Padhye SS; Guin S; Yao HP; Zhou YQ; Zhang R; Wang MH
Mol Pharm; 2011 Dec; 8(6):2310-9. PubMed ID: 22014215
[TBL] [Abstract][Full Text] [Related]
30. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
Chen J; Miller EM; Gallo KA
Oncogene; 2010 Aug; 29(31):4399-411. PubMed ID: 20514022
[TBL] [Abstract][Full Text] [Related]
31. Increased autophagy blocks HER2-mediated breast tumorigenesis.
Vega-Rubín-de-Celis S; Zou Z; Fernández ÁF; Ci B; Kim M; Xiao G; Xie Y; Levine B
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4176-4181. PubMed ID: 29610308
[TBL] [Abstract][Full Text] [Related]
32. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.
Büchler P; Reber HA; Roth MM; Shiroishi M; Friess H; Hines OJ
Neoplasia; 2007 Feb; 9(2):119-27. PubMed ID: 17356708
[TBL] [Abstract][Full Text] [Related]
33. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
[TBL] [Abstract][Full Text] [Related]
34. Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases.
Esparza-López J; Ramos-Elías PA; Castro-Sánchez A; Rocha-Zavaleta L; Escobar-Arriaga E; Zentella-Dehesa A; León-Rodríguez E; Medina-Franco H; Ibarra-Sánchez Mde J
BMC Cancer; 2016 Sep; 16(1):740. PubMed ID: 27645148
[TBL] [Abstract][Full Text] [Related]
35. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
36. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
[TBL] [Abstract][Full Text] [Related]
38. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
Front Oncol; 2019; 9():1377. PubMed ID: 31867280
[TBL] [Abstract][Full Text] [Related]
39. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways.
Guerram M; Jiang ZZ; Yousef BA; Hamdi AM; Hassan HM; Yuan ZQ; Luo HW; Zhu X; Zhang LY
Oncotarget; 2015 Sep; 6(26):21865-77. PubMed ID: 26068969
[TBL] [Abstract][Full Text] [Related]
40. MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy.
Yao HP; Tong XM; Hudson R; Wang MH
J Exp Clin Cancer Res; 2020 Sep; 39(1):198. PubMed ID: 32962738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]